Intensity Therapeutics, Inc. (INTS) Stock Statistics & Valuation Metrics

Intensity Therapeutics, Inc. has a market cap or net worth of $14.94M. The enterprise value is -$1.08M.

Intensity Therapeutics, Inc. has 2,540,518 shares outstanding. The number of shares has decreased by -2.65% in one year.

Intensity Therapeutics, Inc.’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is -99.88%.

The current PE Ratio of Intensity Therapeutics, Inc. is ―. Intensity Therapeutics, Inc.’s PEG ratio is 0.17.

In the last 12 months, Intensity Therapeutics, Inc. had revenue of 0.00 and earned -11.61M in profits. Earnings per share was -8.56.

In the last 12 months, operating cash flow was -9.23M and capital expenditures 0.00, giving a free cash flow of -9.23M billion.

Intensity Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Intensity Therapeutics, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Intensity Therapeutics, Inc. as a current ratio of 5.92, with Debt / Equity ratio of 0.93%

In the past 12 months, Intensity Therapeutics, Inc. has paid 0.00 in taxes.

Intensity Therapeutics, Inc. EV to EBITDA ratio is -10.64, with an EV/FCF ratio of -13.79.

Intensity Therapeutics, Inc. has $11.92M in cash and marketable securities with $110.00K in debt, giving a net cash position of $11.81M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Intensity Therapeutics, Inc. is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy